Herein, we aimed to evaluate the anti-tumor effect of CUDC-907, a dual PI3K-HDAC inhibitor, in esophageal squamous cell carcinoma (ESCC). This evidence concerns the gene HDAC9 and esophageal squamous cell carcinoma.